Finally, our study involved 4 clinical trials published between February 2022 and November 2023, focusing on different endocrine treatment regimens for HR+/HER2- advanced breast cancer, and included a total of 1,290 patients (Table 1). This evidence concerns the gene HR and breast carcinoma.